ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

AXL

AXL receptor tyrosine kinase · also UFO, JTK11, Tyro7, ARK · Fibronectin type III domain containing

5 programs in company-led studies act on AXL, from 5 companies: 4 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
zanzalintinibruleExelixisinhibitorphase 31715 runningKDR, METNCIt
AXL/FLT3/VEGFR2 Inhibitor KC1036ruleBeijing Konruns Pharmaceuticalinhibitorphase 376 runningFLT3, KDRNCIt
gilteritinibruleAstellas Pharmainhibitorphase 3202 runningALK, FLT3, LTKNCIt
vilzemetkibSino Biopharmaceuticalinhibitorphase 382 runningMETthe company's pipeline
adrixetinibruleQurientinhibitorphase 232 runningCSF1RNCIt

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.